NCT02644460View on ClinicalTrials.gov

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions

Diffuse Intrinsic Pontine GliomaBrain Tumor, RecurrentSolid Tumor, RecurrentNeuroblastoma, Recurrent, RefractoryEwing Sarcoma, Recurrent, RefractoryRhabdomyosarcoma, Recurrent, RefractoryOsteosarcoma, Recurrent, RefractoryRhabdoid Tumor, Recurrent, Refractory

Interventions

DRUG

Abemaciclib

Trial Locations (4)

30322

Children's Healthcare of Atlanta, Egleston, Atlanta

30342

Children's Healthcare of Atlanta, Scottish Rite, Atlanta

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Children's Hospital, Phoenix

All Listed Sponsors

lead

Emory University

OTHER

NCT02644460 - Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Biotech Hunter | Biotech Hunter